Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Neoplasm Metastasis × Goserelin × Clear all

Phase

Phase 3 2 Phase 2/3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3 Breast Neoplasms 2 Stage I Prostate Adenocarcinoma AJCC v7 1 Neoplasms 1 Neoplasm Metastasis 1 Castration-resistant Prostate Cancer Patients with Oligometastases 1 Breast Diseases 1

Interventions

Gemcitabine 5 Capecitabine 4 pembrolizumab 3 Fluorouracil 3 Cisplatin 3 vinflunine 2 enzalutamide 2 cabazitaxel 2 abiraterone 2 Ipilimumab 2 Haloperidol 2 Androgen Antagonists 2 vedolizumab 1 trifluridine tipiracil drug combination 1 relugolix 1 racemetyrosine 1 nimotuzumab 1 nilutamide 1 lanreotide 1 histrelin 1 futibatinib 1 exemestane 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 bicalutamide 1 beta-Glucans 1 auricularum 1 atezolizumab 1 apatinib 1 apalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04787744 2026-04-08

VA STARPORT

VA Office of Research and Development

Phase 2/3 Recruiting

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡